Videos

Joselyn Rojas-Quintero, MD, speaks about her team's current research into COPD treatment on this issue of The Respiratory Report.

Panelists discuss how the NefIgArd study findings contribute valuable insights into the efficacy of emerging therapies for IgA nephropathy, emphasizing their role in reducing proteinuria and improving patient outcomes.

Abebaw Yohannes, MSc, PhD, speaks about his team’s pilot study designed to assess the use of duloxetine for patients with COPD and comorbid depression.

Panelists discuss how the PROTECT study’s results enhance the understanding of emerging therapies for IgA nephropathy, focusing on their potential to reduce proteinuria and modify disease progression.

This summarizes the latest in our pulmonology research quarterly newsletter powered by the American Lung Association Research Institute.

In this episode, hosts explore ADA's evolving guidelines championing broader access to CGM and AID systems for personalized diabetes care.

Flemming describes increasing rates of AH among adolescents and young adults, with females facing the greatest increases and worse outcomes than males.

Panelists discuss how the ALIGN trial data inform the development and potential impact of emerging therapies for IgA nephropathy, particularly focusing on their efficacy in reducing proteinuria and addressing disease pathology.

Panelists discuss how the ALIGN trial data inform the development and potential impact of emerging therapies for IgA nephropathy, particularly focusing on their efficacy in reducing proteinuria and addressing disease pathology.

HCPLive spoke with John M. Kane, MD, about phase 2 LB-102 data for schizophrenia.

Piatek discussed findings from a healthcare resource utilization study and a sentiment analysis study presented at ASH 2024.

Pipe discussed a symposium at ASH 2024 about practical implementation of gene therapy in the field.

Panelists discuss how emerging therapies are expected to address the unmet need for treatments that not only reduce proteinuria but also target the underlying immune dysfunction associated with IgA nephropathy.

Panelists discuss how adverse effects associated with corticosteroids can significantly affect patient adherence and quality of life, emphasizing the need for future therapies to strike a balance between efficacy and a more tolerable adverse effect profile.

Schultz discussed the SCtalk trial and its findings at ASH 2024.

Zaheer discussed how this research may be used as a model to help study other therapy transitions as well.

In this episode, hosts discuss a slight dip in US obesity rates, the use of inhaled insulin, and the benefit of mifepristone for HbA1c reduction.

Bendapudi gave an overview of 2 studies presented at ASH 2024 from his Harvard lab.

Rani discussed an in-depth study examining quality of sleep and quality of life in children and adolescents with SCD.

Cell therapy, particularly CAR-T, is expanding into autoimmune diseases like lupus and multiple sclerosis. While promising, safety, efficacy, and broad applicability remain uncertain.

Panelists discuss how current treatments for IgA nephropathy often fall short in addressing the root cause, specifically abnormal IgA production and deposition, and highlight the consequences of prioritizing symptom management, such as proteinuria reduction, over targeting the disease’s underlying pathology.

Panelists discuss how the current treatment landscape for IgA nephropathy presents significant unmet needs, particularly in addressing the underlying causes of the disease and improving patient outcomes.

From groundbreaking therapies to ethical dilemmas, HCPLive’s top podcasts of 2024 delivered expert insights and human stories across medicine.

In this episode of Crisis Point, this year’s news regarding benzene found in acne products is discussed by David Light, Neal Bhatia, MD, and Christopher Bunick, MD, PhD.

To celebrate the close of 2024, we surveyed top cardiologist on what they view as the biggest storyline in their field from the past year.

Panelists discuss how clinicians can effectively shift treatment strategies for IgA nephropathy from merely managing symptoms to actively targeting the root causes of the disease.

Panelists discuss how the reduction of proteinuria is integral to the broader treatment goals for IgA nephropathy, highlighting evidence that supports its role in preventing long-term kidney damage.

In this episode, hosts discuss the efficacy of MariTide for obesity, a head-to-head comparison of semaglutide vs. tirzepatide, and concerns about GLP-1 agonist compounding.

Iron deficiency is currently screened at a ferritin threshold of 15 ug/mL, well below an accepted 25 ug/mL threshold.

Davidow discussed how a new cohort study has helped support findings of an older European study and the need for a prospective trial to confirm the increased risk.